Official Twitter account for Simmaron Research, a non-profit scientifically redefining ME/CFS. Visit our site to learn more.
Joined March 2013
- Tweets 1,665
- Following 422
- Followers 4,144
- Likes 52
341 Photos and videos
Simmaron Research retweeted
Jun 10
Our lab @RedefiningMECFS is a part of drug discovery consortium with MIDD @UWM. A collaborative research (Redox Biology; IF 11.9) identified a novel boronated prodrug that kills TNBC tumor cells by augmenting the production of reactive oxygen species.
sciencedirect.com/science/ar…
4
5
402
On this day, May 12 #WorldMEDay, on behalf of everyone at Simmaron Research Inc. @redefiningMECFS, @ProfAvikRoy and @ggottschalkphd want to thank and recognize all of the patients who have participated in our clinical research protocols, particularly in our low-dose rapamycin projects . Your trust, courage, and commitment make this work possible. We are deeply grateful and honored to do this work alongside you.
3
1
21
342
Why placebo trials in #ME and #LongCovid? It’s how INDUSTRY and PHARMA make investments.
Patients need treatments, and we need drug companies to invest in our disease.
Once we have 1 successful placebo-controlled trial, we’ll attract industry research.
Our placebo RAPAMYCIN trial has an opportunity to be successful, and we’re testing biomarkers to identify the subset that responds.
Even if it doesn’t work for all #MECFS patients, it could be a breakthrough for us all.
Help us do it! simmaronresearch.com/donate
8
24
869
Why placebo trials for #MECFS and #LongCovid?
We have no FDA-approved treatment, because no placebo trial has been successful.
We need them to make breakthroughs happen. It’s how drugs get approved.
Early observational data is encouraging — but it doesn’t change medicine. Rigorous testing does.
Our step-wedge design allows comparison of RAPAMYCIN with placebo while ensuring all participants eventually receive treatment.
If successful, we can prove which subset responds to rapamycin and change medicine, finally.
#ClinicalTrial
2
13
452
Simmaron Research retweeted
1/
@SenMarkey, @SenTimKaine, and @SenDuckworth are championing a FY27 “Dear Colleague” letter for $210M in #LongCOVID research — and it includes #MECFS, #POTS, and #dysautonomia by name. Deadline is FRIDAY. 🧵
ALT Urgent call to action urging the Senate to fund over $210 million for Long COVID and ME/CFS research by April 17 deadline.
2
16
26
1,499
Simmaron Research retweeted
🔬 ARPA-H for high-risk, high-reward LC associated research
The NIH report language is the piece we've been waiting for. It directs funding to INTERVENTIONAL drug trials, biomarker discovery, & real diagnostic tests a required NIH Director briefing to Congress w/in 180 days.
1
3
10
635
Simmaron Research retweeted
Watch! Dr. Avik Roy & Dr. Gunnar Gottschalk of @RedefiningMECFS share how six years of work on the molecular mechanisms of #MECFS has led to one of the only ongoing clinical trials specifically designed around a defined biological target.
youtu.be/OMmjcTKxivU
#MEAwarenessHour
ALT Banner for a Q&A series on ME/CFS research featuring a compass on wood and two scientists from Simmaron Research Institute.
1
15
30
2,651
#ME and #LongCovid patients have no FDA approved treatment, no successful placebo-controlled trial, and no accepted biomarker. That's unacceptable. Our placebo-controlled rapamycin trial is a strategic opportunity to change this, and you can help. Read how testing biomarkers with treatment holds so much promise:
simmaronresearch.salsalabs.o…
1
10
47
1,157
Our new placebo-controlled sub-study of rapamycin will measure:
• autophagy biomarkers (pATG13 and BECLIN-1)
• metabolic pathways using metabolomics
• immune cell changes
• patient symptoms and wearable data
#MECFS and #LongCovid patients deserve evidence-based treatments. Help us fund this rigorous trial so we can get there. simmaronresearch.com/donate
3
18
41
962
Why low-dose rapamycin?
It regulates mTOR and autophagy, pathways that may be disrupted in #MECFS and #LongCOVID.
Our trial measures biomarkers, immune signaling, and metabolic changes to understand why some patients improve, and id who is likely to.
Help us prove the 1st evidence-based treatment for patients with a placebo-controlled trial.
DONATE HERE: simmaronresearch.com/donate
#ME #Autophagy #Rapamycin
5
11
43
1,277
Our placebo-controlled trial will pay for the costs of rapamycin, placebo, safety tests, biomarker tests and clinical work, to ease patient burden and so the results aren’t influenced by costs. #MECFS and #LongCovid patients need evidence-based treatments, and as a non-profit, we need to raise the funds to get there. A generous donor will double your gift, so let’s do it together and break new ground for treatments. #ME simmaronresearch.com/donate
1
14
27
2,369
1️⃣ #MECFS and #LongCOVID affect millions worldwide — yet no @FDA approved treatment exists.
2️⃣ Our team at Simmaron Research is studying low-dose rapamycin, a drug that regulates cellular pathways involved in inflammation and autophagy. 1/3🧵
1
14
44
1,121
3️⃣ Early observational data suggests some #ME patients experience improvements in fatigue and post-exertional malaise. We published those results in Journal of Translational Medicine: link.springer.com/article/10… 2/3
1
3
13
265
4️⃣ Now we are launching a double-blind placebo-controlled trial embedded within our Phase II study to test these findings rigorously and develop a biomarker to help predict responders. This is brand new for #MECFS and #Longcovid.
5️⃣ Your support can help generate the evidence needed for evidence-based treatment. Your gift will be doubled by a generous donor!
Donate today. simmaronresearch.com/donate 3/3
1
3
13
245
Our new placebo-controlled rapamycin trial is based on 4 publications of our own work on the mechanisms & biomarkers disrupting autophagy in a subset of #MECFS & #Longcovid patients. Phase 1 of our rapamycin treatment and biomarker trial was published in the selective Jnl of Translational Medicine: link.springer.com/article/10…. 1/4 🧵
1
15
57
2,097
Mouse Model 2025, demonstrating PEM in animal model resulting from pATG13 (inactive): link.springer.com/article/10…
3/4
2
5
10
436
ATG13 2022, our initial publication finding pATG13 in a subset of #ME patients: sciencedirect.com/science/ar…
4/4
1
4
9
394
We’re launching a placebo-controlled study of rapamycin for #MECFS and #LongCOVID. Early data from our Phase II trial shows promise — now we must test it under rigorous blinded conditions.
Help us make it happen. Donate to support the study.
simmaronresearch.com/donate #ME #Rapamycin
8
39
106
8,668
On behalf of Simmaron's entire research team led by @ggottschalkphd and @ProfAvikRoy, we are incredibly thankful to be producing leading research for #LongCovid, #MECFS and related IACCs. Today on Long-Covid Awareness Day, we remember those lost and see those with the lasting scars suffering.
Science takes time, but we are so happy to see progress being made. Our focus remains on mechanistic clinical trials like our rapamycin clinical trial and identifying molecular pathways that are treatable.
Link to rapamycin phase 1 results in Jnl of Translational Medicine: pubmed.ncbi.nlm.nih.gov/4112…
Link to Inflammation Research paper delineating new mechanisms in #PEM: link.springer.com/article/10…
Sign Up! simmaronresearch.com/signup
3
11
276